{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:37:45Z","timestamp":1787243865199,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical collaboration project between traditional Chinese medicine and Western medicine for major complex diseases","award":["ZDYN-2024-A-066"],"award-info":[{"award-number":["ZDYN-2024-A-066"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shengmai Powder is a classic Traditional Chinese Medicine formula that has been used for centuries to manage cardiovascular diseases characterized by \u201cQi\u2013Yin deficiency with blood stasis.\u201d Optimized New Shengmai Powder (ONSMP), a modern refinement of this formula, has shown clinical efficacy in improving cardiac function in patients with ischemic heart failure. Although our previous studies have demonstrated pronounced cardioprotective effects of ONSMP in preclinical models, the underlying molecular mechanisms\u2014particularly those regulating cardiomyocyte death\u2014remain incompletely understood at the cellular level. Clarifying these mechanisms is essential to bridge traditional therapeutic practice with contemporary scientific validation and to substantiate the clinical utility of ONSMP with modern mechanistic evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study elucidates the molecular mechanisms by which ONSMP inhibits ferroptosis in cardiomyocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>LC\u2013MS\/MS was used to identify active constituents absorbed into the systemic circulation following ONSMP administration in a rat model of ischemic heart failure. A network pharmacology approach was then applied to predict potential therapeutic targets and signaling pathways through which ONSMP may treat ischemic heart failure and inhibit cardiomyocyte ferroptosis, followed by molecular docking and molecular dynamics simulations to evaluate the binding stability between representative compounds and core targets. An oxygen\u2013glucose deprivation (OGD) injury model was established in H9C2 cardiomyocytes to mimic the pathological microenvironment of ischemic heart failure, and cells were treated with ONSMP-containing serum in the presence or absence of core-target inhibitors. Cell viability, iron homeostasis, lipid peroxidation, mitochondrial morphology and function, and the expression of ferroptosis-related genes and proteins were assessed. Finally, the functional contributions of key active constituents to the amelioration of ischemic myocardial injury were further validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 44 absorbed constituents of ONSMP were detected in rat serum. Network pharmacology analysis indicated that ONSMP targets were significantly enriched in pathways related to oxidative stress responses and lipid peroxidation, with the cGMP\u2013PKG signaling pathway emerging as a central hub. Molecular simulations confirmed stable interactions among AKT1, eNOS, PKG1, STAT3, and GPX4. In OGD-injured H9C2 cardiomyocytes, ONSMP-containing serum significantly improved cell viability, reduced intracellular iron accumulation and malondialdehyde levels, preserved mitochondrial integrity, and upregulated GPX4 expression. These effects were associated with activation of the AKT1\/cGMP\u2013PKG axis and were partially abrogated by AKT1 inhibition. Baicalin and Kaempferide were identified as representative bioactive constituents that may contribute to these anti-ferroptotic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ONSMP exerts cardioprotective effects through multiple constituents acting on multiple targets. These effects are mediated, at least in part, by modulation of the cGMP\u2013PKG signaling pathway, which enhances antioxidant defenses and suppresses ferroptosis in cardiomyocytes. Active constituents such as Baicalin and Kaempferide together provide a modern biological basis for the traditional therapeutic efficacy of ONSMP in ischemic heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01364-6","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:34:47Z","timestamp":1772768087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimized New Shengmai Powder suppresses ferroptosis in ischemic cardiomyocytes via cGMP-PKG signalling"],"prefix":"10.1186","volume":"21","author":[{"given":"Zeyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1364_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol. 2023;81:413\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.023.","journal-title":"J Am Coll Cardiol"},{"key":"1364_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","volume":"21","author":"NR Jones","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21:1306\u201325. https:\/\/doi.org\/10.1002\/ejhf.1594.","journal-title":"Eur J Heart Fail"},{"key":"1364_CR3","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074.","journal-title":"J Am Coll Cardiol"},{"key":"1364_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.876","volume":"44","author":"GA Roth","year":"2023","unstructured":"Roth GA, Dorsey H, Decleene N, Razo C, Stark B, Johnson C. The global burden of heart failure: a systematic analysis for the Global Burden of Disease Study 2021. Eur Heart J. 2023;44:ehad655.876. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.876.","journal-title":"Eur Heart J"},{"key":"1364_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-025-00650-y","volume":"12","author":"X Yang","year":"2025","unstructured":"Yang X, Zhao ZP, Shi Y, Han GY, Xu Y, Li YC, et al. The evolving burden of heart failure in China: a 34-year subnational analysis of trends and causes from the global burden of disease study 2023. Mil Med Res. 2025;12:65. https:\/\/doi.org\/10.1186\/s40779-025-00650-y.","journal-title":"Mil Med Res"},{"key":"1364_CR6","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","volume":"28","author":"NL Bragazzi","year":"2021","unstructured":"Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28:1682\u201390. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa147.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1364_CR7","first-page":"413","volume":"30","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang YH. A multicenter, prospective Chinese heart failure registry study: preliminary analysis of etiology, clinical characteristics, and treatment. Chin Circ J. 2015;30(5):413\u20136.","journal-title":"Chin Circ J"},{"key":"1364_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2022.2847","volume":"7","author":"J Harrington","year":"2022","unstructured":"Harrington J, Petrie MC, Anker SD, Bhatt DL, Jones WS, Udell JA, et al. Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction: a review. JAMA Cardiol. 2022;7:1067\u201375. https:\/\/doi.org\/10.1001\/jamacardio.2022.2847.","journal-title":"JAMA Cardiol"},{"key":"1364_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005628","volume":"12","author":"J Li","year":"2019","unstructured":"Li J, Dharmarajan K, Bai X, Masoudi FA, Spertus JA, Li X, et al. Thirty-day hospital readmission after acute myocardial infarction in China. Circ Cardiovasc Qual Outcomes. 2019;12:e005628. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005628.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1364_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","volume":"8","author":"D Jen\u010da","year":"2021","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Stehlik J, Stan\u011bk V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222\u201337. https:\/\/doi.org\/10.1002\/ehf2.13144.","journal-title":"ESC Heart Fail"},{"key":"1364_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.122.059678","volume":"146","author":"Y Sandoval","year":"2022","unstructured":"Sandoval Y, Apple FS, Mahler SA, Body R, Collinson PO, Jaffe AS. High-sensitivity cardiac troponin and the 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guidelines for the evaluation and diagnosis of acute chest pain. Circulation. 2022;146:569\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059678.","journal-title":"Circulation"},{"key":"1364_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00011-023-01758-4","volume":"72","author":"B Bai","year":"2023","unstructured":"Bai B, Ji Z, Wang F, Qin C, Zhou H, Li D, et al. CTRP12 ameliorates post-myocardial infarction heart failure through down-regulation of cardiac apoptosis, oxidative stress and inflammation by influencing the TAK1-p38 MAPK\/JNK pathway. Inflamm Res. 2023;72:1375\u201390. https:\/\/doi.org\/10.1007\/s00011-023-01758-4.","journal-title":"Inflamm Res"},{"key":"1364_CR13","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/eurheartj\/ehab775","volume":"43","author":"MA Kelshiker","year":"2022","unstructured":"Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43:1582\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehab775.","journal-title":"Eur Heart J"},{"key":"1364_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3349\/ymj.2014.55.4.904","volume":"55","author":"R Cheng","year":"2014","unstructured":"Cheng R, Wei G, Yu L, Su Z, Wei L, Bai X, et al. Coronary flow reserve in the remote myocardium predicts left ventricular remodeling following acute myocardial infarction. Yonsei Med J. 2014;55:904\u201311. https:\/\/doi.org\/10.3349\/ymj.2014.55.4.904.","journal-title":"Yonsei Med J"},{"key":"1364_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015502","volume":"9","author":"RA Kloner","year":"2020","unstructured":"Kloner RA. Stunned and hibernating myocardium: where are we nearly 4 decades later? J Am Heart Assoc. 2020;9:e015502. https:\/\/doi.org\/10.1161\/JAHA.119.015502.","journal-title":"J Am Heart Assoc"},{"key":"1364_CR16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116:2672\u201380. https:\/\/doi.org\/10.1073\/pnas.1821022116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1364_CR17","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00022.2018","volume":"99","author":"DP Del Re","year":"2019","unstructured":"Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99:1765\u2013817. https:\/\/doi.org\/10.1152\/physrev.00022.2018.","journal-title":"Physiol Rev"},{"key":"1364_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156783","volume":"142","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yang Z, Wang S, Wang X, Mao J. Natural products and ferroptosis: a novel approach for heart failure management. Phytomedicine. 2025;142:156783. https:\/\/doi.org\/10.1016\/j.phymed.2025.156783.","journal-title":"Phytomedicine"},{"key":"1364_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102932","volume":"113","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yang Z, Wang S, Wang X, Mao J. Ferroptosis and pyroptosis: mediating mechanisms of the cGAS\/STING pathway and therapeutic strategies in heart failure. Ageing Res Rev. 2025;113:102932. https:\/\/doi.org\/10.1016\/j.arr.2025.102932.","journal-title":"Ageing Res Rev"},{"key":"1364_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.adn7030","volume":"386","author":"AR Brown","year":"2024","unstructured":"Brown AR, Hirschhorn T, Stockwell BR. Ferroptosis-disease perils and therapeutic promise. Science. 2024;386:848\u20139. https:\/\/doi.org\/10.1126\/science.adn7030.","journal-title":"Science"},{"key":"1364_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.apsb.2023.02.005","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Wei X, Zhang Q, Wu Y, Xia G, Xia H, et al. The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms. Acta Pharm Sin B. 2023;13:1919\u201355. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.005.","journal-title":"Acta Pharm Sin B"},{"issue":"21","key":"1364_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.13288\/j.11-2166\/r.2015.21.013","volume":"56","author":"XL Wang","year":"2015","unstructured":"Wang XL, Yuan Y, Mao JY, Li B, Zhou RJ, Zhang XL, et al. A single-case crossover randomized controlled trial on Optimized New Shengmai Powder combined with western medicine for chronic heart failure. Zhong Yi Za Zhi. 2015;56(21):1849\u201353. https:\/\/doi.org\/10.13288\/j.11-2166\/r.2015.21.013.","journal-title":"Zhong Yi Za Zhi"},{"key":"1364_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118264","volume":"330","author":"ZY Zhang","year":"2024","unstructured":"Zhang ZY, Yang ZH, Wang S, Feng SL, Wang XL, Mao JY. Regulation of optimized new Shengmai powder on cardiomyocyte apoptosis and ferroptosis in ischemic heart failure rats: the mediating role of phosphatidylinositol-3-kinase\/protein kinase B\/tumor protein 53 signaling pathway. J Ethnopharmacol. 2024;330:118264. https:\/\/doi.org\/10.1016\/j.jep.2024.118264.","journal-title":"J Ethnopharmacol"},{"key":"1364_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ijmm.2017.2891","volume":"39","author":"X Ke","year":"2017","unstructured":"Ke X, Chen J, Peng L, Zhang W, Yang Y, Liao X, et al. Heat shock protein 90\/Akt pathway participates in the cardioprotective effect of exogenous hydrogen sulfide against high glucose-induced injury to H9c2 cells. Int J Mol Med. 2017;39:1001\u201310. https:\/\/doi.org\/10.3892\/ijmm.2017.2891.","journal-title":"Int J Mol Med"},{"key":"1364_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102384","volume":"54","author":"H Li","year":"2022","unstructured":"Li H, Zhu J, Xu YW, Mou FF, Shan XL, Wang QL, et al. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction. Redox Biol. 2022;54:102384. https:\/\/doi.org\/10.1016\/j.redox.2022.102384.","journal-title":"Redox Biol"},{"key":"1364_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102946","volume":"68","author":"L Yao","year":"2023","unstructured":"Yao L, Liang X, Liu Y, Li B, Hong M, Wang X, et al. Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy. Redox Biol. 2023;68:102946. https:\/\/doi.org\/10.1016\/j.redox.2023.102946.","journal-title":"Redox Biol"},{"key":"1364_CR27","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1182\/blood-2011-12-396374","volume":"119","author":"S Gambaryan","year":"2012","unstructured":"Gambaryan S, Friebe A, Walter U. Does the NO\/sGC\/cGMP\/PKG pathway play a stimulatory role in platelets? Blood. 2012;119:5335\u20136. https:\/\/doi.org\/10.1182\/blood-2011-12-396374.","journal-title":"Blood"},{"key":"1364_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102702","volume":"62","author":"P Chang","year":"2023","unstructured":"Chang P, Zhang X, Zhang J, Wang J, Wang X, Li M, et al. BNP protects against diabetic cardiomyopathy by promoting Opa1-mediated mitochondrial fusion via activating the PKG-STAT3 pathway. Redox Biol. 2023;62:102702. https:\/\/doi.org\/10.1016\/j.redox.2023.102702.","journal-title":"Redox Biol"},{"key":"1364_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317. https:\/\/doi.org\/10.1016\/j.redox.2022.102317.","journal-title":"Redox Biol"},{"key":"1364_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05082-3","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang W, Gong M, Zhang W, Mo J, Zhang S, Zhu Z, et al. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3\/GPX4 signalling. Cell Death Dis. 2022;13:630. https:\/\/doi.org\/10.1038\/s41419-022-05082-3.","journal-title":"Cell Death Dis"},{"key":"1364_CR31","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1021\/acsnano.1c08664","volume":"16","author":"K Li","year":"2022","unstructured":"Li K, Lin C, Li M, Xu K, He Y, Mao Y, et al. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy. ACS Nano. 2022;16:2381\u201398. https:\/\/doi.org\/10.1021\/acsnano.1c08664.","journal-title":"ACS Nano"},{"key":"1364_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01804-z","volume":"22","author":"M Jiang","year":"2023","unstructured":"Jiang M, Jike Y, Liu K, Gan F, Zhang K, Xie M, et al. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1. Mol Cancer. 2023;22:113. https:\/\/doi.org\/10.1186\/s12943-023-01804-z.","journal-title":"Mol Cancer"},{"key":"1364_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/1873-3468.13305","volume":"593","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Y, Shen F, Ma X, Zhang M, Hou Y, et al. The flavonoid baicalin improves glucose metabolism by targeting the PH domain of AKT and activating AKT\/GSK3\u03b2 phosphorylation. FEBS Lett. 2019;593:175\u201386. https:\/\/doi.org\/10.1002\/1873-3468.13305.","journal-title":"FEBS Lett"},{"key":"1364_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153035","volume":"63","author":"J Bai","year":"2019","unstructured":"Bai J, Wang Q, Qi J, Yu H, Wang C, Wang X, et al. Promoting effect of baicalin on nitric oxide production in CMECs via activating the PI3K-AKT-eNOS pathway attenuates myocardial ischemia-reperfusion injury. Phytomedicine. 2019;63:153035. https:\/\/doi.org\/10.1016\/j.phymed.2019.153035.","journal-title":"Phytomedicine"},{"key":"1364_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mce.2017.03.027","volume":"448","author":"P Fang","year":"2017","unstructured":"Fang P, Yu M, Zhang L, Wan D, Shi M, Zhu Y, et al. Baicalin against obesity and insulin resistance through activation of AKT\/AS160\/GLUT4 pathway. Mol Cell Endocrinol. 2017;448:77\u201386. https:\/\/doi.org\/10.1016\/j.mce.2017.03.027.","journal-title":"Mol Cell Endocrinol"},{"key":"1364_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119133","volume":"270","author":"H Tang","year":"2021","unstructured":"Tang H, Zeng Q, Tang T, Wei Y, Pu P. Kaempferide improves glycolipid metabolism disorder by activating PPAR\u03b3 in high-fat-diet-fed mice. Life Sci. 2021;270:119133. https:\/\/doi.org\/10.1016\/j.lfs.2021.119133.","journal-title":"Life Sci"},{"key":"1364_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5278218","volume":"2017","author":"D Wang","year":"2017","unstructured":"Wang D, Zhang X, Li D, Hao W, Meng F, Wang B, et al. Kaempferide protects against myocardial ischemia\/reperfusion injury through activation of the PI3K\/Akt\/GSK-3\u03b2 pathway. Mediators Inflamm. 2017;2017:5278218. https:\/\/doi.org\/10.1155\/2017\/5278218.","journal-title":"Mediators Inflamm"},{"key":"1364_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4062\/biomolther.2014.121","volume":"22","author":"YH Jeong","year":"2014","unstructured":"Jeong YH, Park JS, Kim DH, Kim HS. Arctigenin increases hemeoxygenase-1 gene expression by modulating PI3K\/AKT signaling pathway in rat primary astrocytes. Biomol Ther (Seoul). 2014;22:497\u2013502. https:\/\/doi.org\/10.4062\/biomolther.2014.121.","journal-title":"Biomol Ther (Seoul)"},{"key":"1364_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/cbdd.13659","volume":"95","author":"H Li","year":"2020","unstructured":"Li H, Yang C, Lan M, Liao X, Tang Z. Arctigenin promotes bone formation involving PI3K\/Akt\/PPAR\u03b3 signaling pathway. Chem Biol Drug Des. 2020;95:451\u20139. https:\/\/doi.org\/10.1111\/cbdd.13659.","journal-title":"Chem Biol Drug Des"},{"key":"1364_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.yjmcc.2021.12.007","volume":"165","author":"Z On\u00f3di","year":"2022","unstructured":"On\u00f3di Z, Visnovitz T, Kiss B, Hambalk\u00f3 S, Koncz A, \u00c1gg B, et al. Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype. J Mol Cell Cardiol. 2022;165:19\u201330. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.12.007.","journal-title":"J Mol Cell Cardiol"},{"key":"1364_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12012-011-9112-4","volume":"11","author":"SL Pereira","year":"2011","unstructured":"Pereira SL, Ramalho-Santos J, Branco AF, Sard\u00e3o VA, Oliveira PJ, Carvalho RA. Metabolic remodeling during H9c2 myoblast differentiation: relevance for in vitro toxicity studies. Cardiovasc Toxicol. 2011;11:180\u201390. https:\/\/doi.org\/10.1007\/s12012-011-9112-4.","journal-title":"Cardiovasc Toxicol"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01364-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:34:50Z","timestamp":1772768090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01364-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01364-6","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 8023, revised 1978) and were approved by the Institutional Animal Ethics Committee of Tianjin University of Traditional Chinese Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}